Clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer.
SpringWorks Therapeutics, Inc., headquartered in Stamford, Connecticut, specializes in acquiring, developing, and commercializing medicines aimed at addressing unmet needs in rare diseases and cancer. The company's primary focus revolves around advancing innovative therapies that cater to underserved patient populations.
At the forefront of its pipeline is nirogacestat, an oral gamma secretase inhibitor currently undergoing Phase III clinical trials for the treatment of desmoid tumors. Additionally, SpringWorks Therapeutics is actively developing mirdametinib, an oral MEK inhibitor. This compound is in Phase 2b trials for neurofibromatosis type 1-associated plexiform neurofibromas and Phase 1/2a trials for NF1-PN. The company is also exploring mirdametinib in combination with lifirafenib in Phase 1b/2 trials for advanced or refractory solid tumors.
SpringWorks Therapeutics' commitment to innovation extends to its development of BGB-3245, an oral inhibitor targeting activating BRAF mutations, currently in Phase I clinical trials. The company collaborates extensively with leading organizations such as BeiGene, GlaxoSmithKline, and Allogene to explore combination therapies involving nirogacestat and mirdametinib. Strategic license agreements with Pfizer, Katholieke Universiteit Leuven, Flanders Institute for Biotechnology, and Dana-Farber Cancer Institute further enhance its robust portfolio of therapeutic solutions.
Founded in 2017, SpringWorks Therapeutics continues to expand its impact through clinical collaborations with industry leaders like Janssen Biotech, Precision BioSciences, Seagen Inc., and AbbVie Inc. With a strong emphasis on advancing transformative treatments, the company remains dedicated to improving outcomes and quality of life for patients facing challenging medical conditions worldwide.